




ESMO Preceptorship on Hereditary Cancer Genetics

PROGRAMME

**ESMO
PRECEPTORSHIP**

**LUGANO SWITZERLAND
11-12 MAY 2026**

CO-CHAIRS

Judith Balmaña, Spain

Marjolijn Ligtenberg, Netherlands

esmo.org

ESMO

ESMO PRECEPTORSHIP PROGRAMME HEREDITARY CANCER GENETICS

Multidisciplinary management, standards of care
and future perspectives

Lugano, Switzerland
11-12 May 2026

CO-CHAIRS

Judith Balmaña, Spain
Marjolijn Ligtenberg, Netherlands

SPEAKERS

Stefan Aretz, Germany
Iosune Baraibar, Spain
Svetlana Lagercrantz, Sweden
Matteo Lambertini, Italy
Marc Tischkowitz, United Kingdom

LEARNING OBJECTIVES

- To learn about the best clinical practice in the multidisciplinary management of hereditary cancer syndromes
- To understand the molecular basis and heterogeneity of genetic susceptibility to develop cancer
- To learn how to recognise, diagnose, treat and provide prevention recommendations to patients with a germline genetic susceptibility

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Monday, 11 May 2026

09:00-09:10 10'	Welcome and introduction	Judith Balmaña, ES Marjolijn Ligtenberg, NL
09:10-10:40 90'	SESSION 1 Challenges in hereditary cancer in 2026	Chair: Judith Balmaña, ES
25'	Overview of the clinical challenges in hereditary cancer: Identification, treatment and prevention. The role of ERN-GENTURIS	Svetlana Lagercrantz, SE
25'	Challenges of genetic testing in cancer: Mode of inheritance, interpretation of pathogenicity, cancer penetrance	Marjolijn Ligtenberg, NL
25'	Challenges in risk communication in hereditary cancer	Svetlana Lagercrantz, SE
15'	Q&A	All
10:40-11:10	Coffee break	
11:10-12:40 90'	SESSION 2 Hereditary gastrointestinal cancers	Chair: Marjolijn Ligtenberg, NL
25'	What an oncologist needs to know about colorectal cancer and polyposis syndromes	Stefan Aretz, DE
25'	Mismatch repair deficiency: Somatic versus germline origin, a target for cancer prevention and targeted cancer therapy	Iosune Baraibar, ES
25'	Hereditary gastric cancer	Marc Tischkowitz, UK
15'	Q&A	All
12:40-13:40	Lunch	
13:40-15:30 110'	SESSION 3 What an oncologist needs to know about hereditary prostate cancer and renal cancer	Chair: Marjolijn Ligtenberg, NL
25'	Germline susceptibility to prostate cancer: What genes to test, when, and why?	Marjolijn Ligtenberg, NL
25'	Germline susceptibility to renal cancer: From genes to targeted therapy	Stefan Aretz, DE
15'	Q&A	All
45'	Participants clinical case discussion (3x15')	Faculty
15:30-16:00	Coffee break	
16:00-17:35 95'	SESSION 4 Challenges in identification of hereditary susceptibility	Chair: Judith Balmaña, ES
25'	Recognising variants of germline origin in tumour sequencing: ESMO recommendations	Marjolijn Ligtenberg, NL

25'	TP53-hereditary cancer susceptibility: Diagnostic challenges and management	Svetlana Lagercrantz, SE
15'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
19:30	Dinner	

Tuesday, 12 May 2026

09:00-10:30 90'	SESSION 5 Hereditary breast and ovarian cancer	Chair: Marjolijn Ligtenberg, NL
25'	Germline susceptibility to HBOC in 2026	Marc Tischkowitz, UK
25'	Principles of targeted therapies in patients with a germline susceptibility to breast and ovarian cancer	Judith Balmaña, ES
25'	Fertility and reproductive options in women with a genetic susceptibility	Matteo Lambertini, IT
15'	Q&A	All
10:30-11:00	Coffee break	
11:00-12:00 60'	SESSION 6 Participants clinical case discussion	Chairs: Judith Balmaña, ES Marjolijn Ligtenberg, NL
60'	Participants clinical case discussion (4x15')	Faculty
12:00-12:15 15'	Conclusion and farewell	Judith Balmaña, ES Marjolijn Ligtenberg, NL
12:15-13:15	Lunch	

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion